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ABSTRAK
Leukemia Limfoblastik Akut (LLA) adalah penyakit neoplasma yang dihasilkan dari perpindahan somatik multistep progenitor 
limfoid di sumsum tulang, ditandai maturation arrest, proliferasi tidak terkendali seri limfoid serta penumpukan limfoblas di sumsum 
tulang dan darah tepi. Kelainan terkait aktivitas proliferasi sel berkaitan dengan kendali apoptosis. Penelitian ini bertujuan mengetahui 
perbandingan persentase proliferasi dan apoptosis limfoblas di darah tepi pasien LLA anak sebelum dan sesudah kemoterapi tahap 
induksi. Subjek penelitian sebesar 12 pasien LLA anak kasus baru yang diperiksa sebelum dan sesudah kemoterapi tahap induksi. Jenis 
penelitian ini cohort prospektif tanpa pembanding. Pemeriksaan proliferasi limfoblas dilakukan menggunakan spesimen darah tepi 
sedangkan pengecatannya menggunakan reagen PI/RNase. Pemeriksaan apoptosis limfoblas dilakukan menggunakan spesimen darah 
tepi sedangkan pengecatannya menggunakan reagen FITC Annexin V. Pembacaan proliferasi dan apoptosis limfoblas menggunakan alat 
BD FACSCallibur dengan metode flow cytometry. Rerata persentase proliferasi dan apoptosis limfoblas sebelum kemoterapi tahap induksi 
7,84%±7,50 dan 11,50%±8,60 sesudah kemoterapi tahap induksi 3,2%±1,89 dan 13,42%±8,10. Persentase proliferasi limfoblas di 
darah tepi sesudah pemberian kemoterapi tahap induksi terdapat penurunan bermakna, sedangkan pemeriksaan apoptosis limfoblas 
didapatkan peningkatan yang tidak bermakna. Persentase proliferasi limfoblas di darah tepi sesudah kemoterapi tahap induksi terdapat 
penurunan bermakna, sehingga dapat dipergunakan sebagai peramal keberhasilan pengobatan pasien LLA anak. Pemeriksaan apoptosis 
limfoblas tidak terdapat perbedaan bermakna sebelum dan sesudah kemoterapi tahap induksi. Perlu penelitian lebih lanjut untuk 
menganalisis hasil yang didapat.
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ABSTRACT
Acute Lymphoblastic Leukemia (ALL) is a neoplastic disease in the multistep lymphoid progenitor of the bone marrow, 
characterized by maturation arrest, uncontrolled proliferation of lymphocytes, lymphoblast accumulation in bone marrow and 
peripheral blood. Disorders related to the activity of cell proliferation are closely related to the control of apoptosis. The aim of this 
study was to compare the percentage of lymphoblast proliferation and apoptosis in peripheral blood of pediatric ALL before and after 
chemotherapy induction phase. Subjects were 12 new cases of pediatric ALL, examined before and after chemotherapy induction 
phase. This research was a prospective cohort without comparison. Lymphoblast proliferation examination was performed using 
peripheral blood specimens and staining by PI/RNase reagent, while lymphoblast apoptosis examination used staining by Annexin 
V FITC reagent. Examination of lymphoblast proliferation and apoptosis was done by BD FACSCalibur using flow cytometry. Mean 
percentage of lymphoblast proliferation and apoptosis before chemotherapy induction phase was 7.84%±7.50 and 11.50%±8.60, after 
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chemotherapy induction phase 3.2%±1.89 and 13.42%±8.10. In the peripheral blood lymphoblast proliferation percentage decreased 
after chemotherapy induction phase compared to before in pediatric ALL. Examination of lymphoblast apoptosis showed no significant 
improvement. Percentage of lymphoblast proliferation in peripheral blood after chemotherapy induction phase decreases, so it could 
be used to predict therapeutic efficacy in pediatric ALL. Lymphoblast apoptosis examination showed no significant difference. Further 
research is needed to analyze these results.
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INTRODUCTION
Acute Lymphoblastic Leukemia (ALL) is the most 
common malignancy in children, approximately 25% 
of all cases of malignancy in children. The incidence 
of leukemia in Indonesia 2.5–4.0 per 100,000 children 
is estimated to be 2000–2300 new cases every year.1 
The disease is characterized by maturation arrest, 
uncontrolled proliferation of bone marrow and 
lymphoid progenitor lymphoblast accumulation in the 
bone marrow and peripheral blood.2
The molecular process that regulates the cell cycle 
and mechanisms of malignant cells escaping the 
control of the cell cycle, as well as the cessation of 
proliferation associated lifetime of the cells, is the key 
to understanding normal and malignant cells. The cell 
cycle is a process that is organized regularly to copy 
and pass on genetic information from one generation 
to the next. Cell cycle or normal cell proliferation 
takes place through a cycle of four sequential phases, 
each referred to as phase G1 (first gap), S phase 
(DNA synthesis), G2 phase (gap 2) and M-phase 
(mitosis).3
Disorders related to the activity of cell proliferation 
are also closely related to the control of apoptosis. 
Failure to implement the mechanism of cancer 
cell apoptosis is one of the factors underlying the 
increasing growth of cancer, genetic instability of the 
cells in question and resistance to chemotherapy. The 
purpose of cancer therapy is to kill cancer cells and 
restore the impaired gene function, among others 
restore the apoptotic function. One indicator of the 
success of cancer therapy is the decreased proliferation 
and increased apoptosis of cancer cells. Research on 
cell proliferation has been performed by Ffrench and 
colleagues4 in pediatric Acute Lymphoblastic Leukemia 
(ALL) showed a longer remission time when the level 
of G2+M phase is higher.4 Research on apoptosis 
by Kaparou and colleagues5 in pediatric ALL found 
increased levels of apoptosis in remission when 
compared to the current diagnosis by the expression 
of FAS (24.0±6.1% compared to 8.0±1.9%, p=0.035).5 
Until now, a study comparing the percentage of 
lymphoblast proliferation and apoptosis in pediatric 
ALL before and after induction phase of chemotherapy 
has not been studied in the Dr. Soetomo Hospital 
Surabaya.
The aim of this study was to compare and analyze 
the differences in the percentage of lymphoblast 
proliferation and apoptosis in peripheral blood before 
and after the induction phase of chemotherapy in 
pediatric ALL. This study is expected to be one of the 
indicators of the success of chemotherapy in pediatric 
ALL.
METHODS
The study was observational analytical with a 
prospective cohort design without comparison. This 
research was conducted in the Hemato-Oncology 
patient ward, Department of Pediatrics, Dr. Soetomo 
Hospital-Faculty of Medicine, University of Airlangga, 
as a determination of diagnosis and sampling. Sample 
processing (examination of lymphoblast proliferation 
and apoptosis) was conducted at the Laboratory of 
Clinical Pathology, Dr. Soetomo Hospital Surabaya. 
This study was conducted from February 2016 to 
April 2016. The subjects were patients in Hemato-
Oncology Ward, Department of Pediatrics, Dr. Soetomo 
Hospital-Faculty of Medicine, University of Airlangga, 
newly diagnosed with Acute Lymphoblastic Leukemia 
and who met the inclusion criteria and no one in 
accordance with the exclusion criteria.
Inclusion criteria were patients with ALL aged 
1 month to 18 years (newly diagnosed) and who 
underwent regular chemotherapy induction phase. The 
protocol of chemotherapy induction phase was based 
on ALL Protocol Indonesia 2013.6
Exclusion criteria were acute lymphoblastic leukemia 
patients who had received steroid therapy or cytostatic 
previously, as well as patients who experienced an 
infection (toxic granules found in blood smears and or 
shift to the left in a complete blood count).
Calculation of sample size was obtained by 
using the Lemeshow‘s formula so that the minimum 
sample required was 12 samples for each inspection 
of lymphoblast proliferation and apoptosis in 
pediatric ALL before and after induction phase of 
chemotherapy. 
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Specimens used for the inspection lymphoblast 
proliferation and apoptosis was 3 mL venous blood 
with EDTA anticoagulant. Materials for examination 
of lymphoblast proliferation were PBS, Ficoll-Hypaque, 
cold 70% Ethanol, PI/RNase reagent. Materials for 
examination lymphoblast apoptosis were PBS, Ficoll-
Hypaque, FITC Annexin V reagent and binding 
buffer. Tools used for specimen collection were paper 
alcohol swab, gloves and sterile syringes. Tools used 
to store the specimen were EDTA tube for storing 
specimen examination of lymphoblast apoptosis and 
proliferation, a refrigerator -20°C was also needed to 
store specimens of lymphoblast proliferation. Tools for 
examination of the proliferation and apoptosis were 
Valcon tubes, centrifuge tubes, micropipettes, swing 
centrifuge, Pasteur pipettes, FACS Calibur by flow 
cytometry method.
Examination of lymphoblast proliferation before 
chemotherapy induction phase used cells generated 
from PBMC of ALL patients who had never undergone 
chemotherapy induction phase and examined using 
PI staining by PI/RNase reagents and read using 
a flow cytometry method by BD FACS Calibur. 
Re-examination was done after patients underwent 
chemotherapy induction phase. Lymphoblast 
proliferation inspection unit was percentage of G2/M 
and S in the scattergram as seen in Figure 1.7
Lymphoblast apoptosis examination prior to 
chemotherapy induction phase was cells produced 
from PBMC ALL patients who had never undergone 
chemotherapy induction phase and was examined 
using Annexin V FITC reagent and performed by BD 
FACSCalibur using flow cytometry. Re-examination 
was done after patients underwent chemotherapy 
induction phase. Examination of lymphoblast apoptosis 
was expressed by percentage on the upper and lower 
right quadrant (upper right/UR) and lower right/LR) 
scattergram as seen in Figure II.2 and II.3.8 
Figure 1.  Proliferation pattern in scattergram.
The results were shown as the lymphoblast Proliferation percentage value G2 and S
Figure 2.  Apoptosis Pattern in scattergram. 
The result at the upper and lower right quadrant 
showed the area of apoptosis
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RESULTS AND DISCUSSION
In the first examination, 37 new ALL patients who 
met the inclusion criteria were found, but during 
the time 10 patients died, 7 patients did not return 
so both were categorized as drop out criteria and 8 
patients had a low sample volume or the process was 
less precise, so the results could not be analyzed. The 
final results were obtained in 12 patients who could be 
followed for the examination of both proliferation and 
apoptosis lymphoblasts after undergoing chemotherapy 
patients completed the induction phase.
Characteristics of the samples consisted of gender, 
age, hemoglobin, leukocyte count and platelet count 
as seen in Table 1.
Patients with pediatric ALL studied were mostly 
boys as many as 9 (75%), while 3 (25%) were 
girls. This was consistent with the literature which 
mentioned that ALL types of T-cell and B-cell were 
male dominated.9 Research on ALL in children 
conducted by Ffrench and his colleagues4 showed the 
percentage of males 67% while females 33%.4
The mean age of patients with ALL in children was 
7.33 with a standard deviation of 3.94. The youngest 
Table 1. Characteristics of pediatric acute lymphoblastic leukemia research subjects
Characteristics of research subjects amount % Mean SD
Sex
Boy 9 75
Girl 3 25
Age 7.33 3.94
2 years 1 8.3
3 years 2 16.7
4 years 1 8.3
6 years 2 16.7
7 years 1 8.3
9 years 1 8.3
12 years 4 33.3
Hb before chemotherapy induction phase 9.31 2.65
Hb after chemotherapy induction phase 11.77 1.81
Leukocytes before chemotherapy induction phase 76.90 167.51
Leukocytes after chemotherapy induction phase 8.90 15.05
Platelets before chemotherapy induction phase 70.39 43.20
Platelets after chemotherapy induction phase 214.53 138.79
Figure 3.  Apoptosis result.
Results circled in red were the percentages of apoptosis
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was 2 years old, while the oldest was 12 years of age, 
the most were aged 12, four (33.3%) children. This 
was in contrast with the literature that stated that the 
highest age group of children was two to four years.9 
This difference may be due to the number of research 
subjects.
The mean hemoglobin levels of pediatric ALL 
research subjects before chemotherapy induction phase 
was 9.31 g/dL. After chemotherapy induction phase, 
the mean hemoglobin levels became 11.77 g/dL. The 
mean leukocytes of pediatric Acute Lymphoblastic 
Leukemia research subjects before chemotherapy 
induction phase was 76.9×103/uL. After chemotherapy 
induction phase, the mean leukocytes became 
8.9×103/uL. The mean platelets of pediatric ALL 
research subjects before chemotherapy induction phase 
was 70.39×103/uL. After chemotherapy induction 
phase, the mean platelets became 214.53×103/uL. 
Conditions of anemia and thrombocytopenia in the 
state before chemotherapy induction phase can be 
caused by hematopoietic cell suppression by leukemia 
cells accumulating in the bone marrow. This will lead 
to anemia, thrombocytopenia in the bone marrow and 
peripheral blood, whereas leukocytes dominated by 
lymphoblast cells will increase. Acute lymphoblastic 
leukemia circumstance will occur as a proliferative 
disorder causing uncontrolled proliferation while 
apoptotic function was impaired.9 This situation 
was different when seen after administration of 
chemotherapy induction phase and it turned out that 
in this study all patients were remission.
Wilcoxon Signed Ranked Test Results of 
lymphoblast proliferation of pediatric ALL in peripheral 
blood before and after chemotherapy induction phase 
were as follows:
Table 2.  Wilcoxon Signed Rank Test Analysis lymphoblast 
proliferation of pediatric acute lymphoblastic 
leukemia in peripheral blood as research subjects 
before and after chemotherapy induction phase
Lymphoblast 
proliferation (%)
Mean SD
Value p 
(1-tailed)
Before chemotherapy 
induction phase 
7.84 7.75 0.0075
After chemotherapy 
induction phase
3.20 1.89
The mean patient lymphoblast proliferation of 
pediatric ALL research subjects in peripheral blood 
before chemotherapy induction phase was 7.84%, 
with a standard deviation of 7.75. After chemotherapy 
induction phase, the mean patient lymphoblast 
proliferation of pediatric ALL as research subjects 
fell to 3.2%, with a standard deviation of 1.89. 
Wilcoxon Signed Rank Test resulted in a p value of 
0.0075<0.05 so it could be concluded as a significant 
difference in lymphoblast proliferation of pediatric ALL 
research subjects in peripheral blood before and after 
chemotherapy induction phase.
Results of paired samples t test of apoptosis 
pediatric ALL as research subjects before and after 
chemotherapy induction phase were as follows:
Table 3.  Paired t test samples lymphoblast apoptosis of 
pediatric acute lymphoblastic leukemia in peripheral 
blood as research subjects before and after 
chemotherapy induction phase
Apoptosis (%) Mean SD Value p
Before chemotherapy 
induction phase
11.50 8.60 0.601
After chemotherapy induction 
phase
13.42 8.10
The mean patient lymphoblast apoptosis of 
pediatric ALL as research subjects in peripheral blood 
before chemotherapy induction phase was 11.5% 
with a standard deviation of 8.6. After chemotherapy 
induction phase, the mean patient lymphoblast 
apoptosis pediatric ALL as research subjects in 
peripheral blood was 13.42% with a standard deviation 
of 8.1. Paired t test samples resulting in a p value of 
0.3005>0.05 concluded that there were no significant 
differences in lymphoblast apoptosis pediatric ALL as 
research subjects in peripheral blood before and after 
chemotherapy induction phase. This study using data 
from another patient group of examination lymphoblast 
apoptotic of bone marrow aspiration showed that the 
mean of lymphoblast apoptotic in bone marrow before 
chemotherapy induction phase was 10.11% and after 
was 30.11%, the results revealed a significant increase 
of lymphoblast apoptotic with a p value 0.200.
Chemotherapy treatment in induction phase by 
using a class of glucocorticoids such as prednisone or 
dexamethasone could give meaningful antileukemic 
effects. Effects on lymphoid cells induced apoptosis and 
resistance of the cell cycle. Kofler10 insisted that the 
ongoing repression of the metabolic pathways through 
the glucocorticoid receptor regulation contributed to 
the inhibition of cell cycle.10 Methotrexate, which is one 
example of a series of induction therapy has the effect 
of competition in inhibiting dihydrofolate reductase, 
which is an enzyme participating in the synthesis of 
tetrahydrofolate in producing folic acid. Folic acid is 
required for DNA synthesis, thus causing inhibition 
to methotrexate therapy DNA.11 Vincristine of the 
same dose will inhibit increase of cell proliferation 
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at 24 hours, 48 hours and 72 hours with levels of 
0.113±0.012, 0.078±0.009 and 0.051±0.008 μM.12 Use 
of daunorubicin caused restraint DNA repair through 
topoisomerase II inhibitor that produces barriers of 
DNA synthesis and RNA.13 Research conducted by Sur 
and his colleagues demonstrated that asparaginase 
inhibited proliferation of leukemic cells by showing 
the loss of S phase of the cycle cell.14
Effects of chemotherapy can impact lymphoblast 
cell necrosis or premature apoptotic examination, 
which caused not be detected as apoptotic bodies in 
this study. A research conducted by Liu15 proved their 
lymphoblast apoptosis increase of about <1% to 38% 
in peripheral blood of patients with pediatric acute 
lymphoblastic leukemia monitored after 24 hours of 
administration of chemotherapy compared to apoptosis 
induction phase starting about 3% to 29%.15 A Study 
conducted by Laane16 stated that dexamethasone 
induced apoptosis was associated with the activation 
of Bax (p=0.045) and the down-regulation of Bcl-2 
(p=0.016) and or Bcl-xL (p=0.004) in cell cultures 
of pediatric ALL, as well as showing an increase in 
apoptosis after administration for 24 hours, 36 hours 
and 48 hours.16  
CONCLUSIONS AND SUGGESTIONS
Conclusions drawn based on the results and 
discussion of this research are as follows: There was a 
significant decrease in the percentage of lymphoblast 
proliferation in peripheral blood of pediatric ALL 
after chemotherapy induction phase; There was 
no significant increase in lymphoblast apoptosis in 
peripheral blood of pediatric ALL before and after 
chemotherapy induction phase; The percentage of 
lymphoblast proliferation in peripheral blood can be 
used as an alternative to monitor the success of therapy 
in pediatric ALL.
Based on the above results, it is recommended: 
Long-term observation should be made to complete 
the management of chemotherapy; There should be 
an uniformity span of the specimen at the time prior to 
completion of chemotherapy induction phase; A specific 
marker of lymphocytes examination (examination CD 
3, CD19) for separating the monocyte series is clearly 
needed.
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